Ezzedine, Khaled http://orcid.org/0000-0002-5468-4589
Soliman, Ahmed M. http://orcid.org/0009-0008-8632-1396
Li, Chao http://orcid.org/0000-0003-2124-3282
Camp, Heidi S. http://orcid.org/0009-0003-2632-015X
Pandya, Amit G. http://orcid.org/0000-0002-3916-2651
Funding for this research was provided by:
AbbVie Inc.
Article History
Received: 21 June 2023
Accepted: 2 August 2023
First Online: 5 September 2023
Declarations
:
: K. Ezzedine is a consultant for AbbVie, Incyte, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio. A.M. Soliman, C. Li, and H.S. Camp are full-time employees of AbbVie Inc. and may hold AbbVie stock and/or stock options. A.M. Soliman is also a co-inventor on AbbVie patents. A.G. Pandya has served as an investigator for Immune Tolerance Network, Incyte, and Pfizer. He is a consultant for AbbVie, Arcutis, Avita Medical, Immune Tolerance Network, Incyte, Pfizer, Trifecta, TWi, Viela Bio, Vyne, and Villaris and holds stock options for Tara Medical and Zerigo Health.
: This retrospective cohort analysis using the Merative MarketScan Commercial Database did not require approval from an institutional review board or ethics committee nor was written informed consent required.